Optimizing Therapy for Osteoporosis

Aligning Patient Profiles with Evidence-Based Treatment for Osteoporosis—A Best Practice Update

HealthWRAP CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Release Date:

December 15, 2008

Expiration Date:

December 15, 2010

Intended Audience:

This program is designed for all practitioners with the following specialties or subspecialties:

• Internal medicine specialists
• Primary care special ists
• Family medicine specialists
• Endocrinologists
• Bone metabolism experts
• Women’s health physi cians
• Preventive medicine specialists
• Geriatricians
• Gynecologists
• Osteopathic physicians
• Nurse practitioners
• Geriatric nurse practitioners
• Rheuma tologists
• Consulting pharmacists

Registration:

Enrollment for this HealthWRAP is complimentary, and clinicians are invited to participate in this CME-certified HealthWRAPs and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

Supported by an independent educational grant from Novartis Pharmaceuticals.
 

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Program Faculty:

Felicia Cosman, MD
Professor of Clinical Medicine
Columbia University School of Medicine
New York, New York
Clinical Director, National Osteoporosis Foundation
Medical Director, Clinical Research Center
Helen Hayes Hospital
Haverstraw, New York

Faculty Disclosures:

Dr. Cosman reports that she has received research/grant funds from Eli Lilly and Company and consultant fees from Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Merck & Co., Inc., Pfizer, and Roche. Dr. Cosman has also been on speakers bureau for Eli Lilly and Company, Merck & Co., Inc., and Roche

Educational Objectives:

After viewing this program, physicians, pharmacists, and other healthcare providers will:

• Learn to risk stratify patients at risk for osteoporosis and/or related complications and identify optimal therapeutic approaches.
• Learn to undertake a systematic evaluation of patients at risk for osteoporosis, including radiological examination and appropriate laboratory markers.
• Learn evidence-based approaches to reducing progression of osteoporosis, and reducing risk of fracture complications.
• Learn how to select safe and effective pharmaco therapy for prevention and treatment of postmeno pausal osteoporosis.
• Learn how landmark trials and analyses focusing on BMD, bisphosphonate therapy, predictive risk, and fracture reduction should guide clinical management of patients with osteoporosis.
  

Disclaimer:

Copyright © 2008 by Pharmatecture, LLC. All rights reserved. Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this HealthWRAP reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this HealthWRAP is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this HealthWRAP is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This HealthWRAP is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This HealthWRAP is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Copyright © 2008 All rights reserved